Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its...

|About: Cardiovascular Systems, Inc. (CSII)|By:, SA News Editor

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its treatment therapy for patients with severely calcified coronary lesions had exceeded expectations by a significant margin. The study is reviewing the safety and effectiveness of it's orbital atherectomy technology and is the first Investigational Device Exemption study to seek approval for treating these lesions.